United Kingdom
North West; Greater Manchester; Greater Manchester North
Location of affected unit(s)
Manufacture Of Chemicals And Pharamceuticals
Manufacture Of Basic Pharmaceutical Products And Pharmaceutical Preparations
21.10 - Manufacture of basic pharmaceutical products

150 jobs
Number of planned job losses
Job loss
Announcement Date
11 January 2021
Employment effect (start)
11 January 2021
Foreseen end date
11 October 2021


Catalent UK, the British subsidiary of the US-based global pharmaceutical company, has confirmed that it will close its plant in Bolton, Greater Manchester, in the north west of England, over the next nine months. The closure will make 150 jobs redundant, which will be relocated to the company sites in the US, Germany and Bathgate, Scotland.

A representative of the company said the decision about the planned closure was made after reviewing the demand for clinical trial supply services in the UK.

A representative of the trade union Unite said the closure was due to the UK leaving the European Union and added that the job loss was a ‘blow’ to the employees and the local economy.

Catalent develops and manufactures drugs, gene therapies and consumer health products. It employs more than 14,000 people globally. The company currently has five sites across England and Scotland, with the Bolton site specialising in clinical trial supplies.



Eurofound (2021), Catalent, Relocation in United Kingdom, factsheet number 103198, European Restructuring Monitor. Dublin, https://restructuringeventsprod.azurewebsites.net/restructuring-events/detail/103198.